COMP <GO>
TMCI vs CLPT // DIVIDEND YIELD & FCF PAYOUT SAFETY
Treace Medical Concepts Inc. (NASDAQ) VS. ClearPoint Neuro Inc. (NASDAQ) • 15-METRIC TALLY: TMCI 6
— CLPT 3
■ METRIC PARITY
LAST: $5.06 (+4.76%) • MKT CAP: $329.1M
dividend-safety
0.00%
LAST: $10.69 (+1.23%) • MKT CAP: $342.7M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMCI VS. CLPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMCI | CLPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.80% | 61.40% | +18.40 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.40% | -35.00% | +2.60 | TMCI | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.96% | -7.13% | -1.83 | CLPT | /fcf-yield <GO> |
| Operating Margin | -25.50% | -60.00% | +34.50 | TMCI | /operating-margins <GO> |
| Net Profit Margin | -27.70% | -60.00% | +32.30 | TMCI | /net-margins <GO> |
| Revenue Growth (YoY) | 1.60% | 17.80% | -16.20 | CLPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.90 | 0.20 | +0.70 | TMCI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 48.9 | +2.69 | TMCI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $329.1M | $342.7M | -$13.6M | CLPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMCI REV | CLPT REV | TMCI GROSS % | CLPT GROSS % | TMCI FCF | CLPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $212.7M | $37.0M | 79.8% | 61.4% | -$29.5M | -$24.4M |
| FY 2024 | $209.4M | $31.4M | 80.4% | 60.9% | -$48.8M | -$9.2M |
| FY 2023 | $187.1M | $24.0M | — | — | -$34.6M | -$13.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMCI // BETA —
CLPT // BETA —